Schedule 13G Filing by Trails Edge Capital Partners, LP

Trails Edge Capital Partners, LP, along with its affiliates Trails Edge Biotechnology Master Fund, LP and Ortav Yehudai, have filed a Schedule 13G, reporting beneficial ownership of 126,010 shares of Sensei Biotherapeutics, Inc. common stock. This represents 9.9% of the outstanding shares as of February 18, 2026. The ownership primarily consists of shares held directly by Trails Edge Biotechnology and shares underlying convertible preferred stock. The filing clarifies that this ownership is not for the purpose of influencing the control of the issuer.